

Can't fill your Vimpat prescription? Learn about alternative seizure medications like Briviact, Trileptal, and Keppra that your doctor may consider.
If you've been prescribed Vimpat (Lacosamide) for partial-onset seizures and you're having trouble filling your prescription, you might be wondering: are there other medications that could work for me?
The short answer is yes — there are several well-established alternatives. But switching seizure medications is never something you should do on your own. Any change needs to be guided by your neurologist, who can evaluate your seizure type, medical history, and other medications to find the safest option.
This article will help you understand how Vimpat works, introduce some common alternatives, and give you the information you need to have a productive conversation with your doctor.
Vimpat is the brand name for Lacosamide, an antiepileptic drug (AED) manufactured by UCB Pharma. It's FDA-approved as both monotherapy and adjunctive therapy for partial-onset (focal) seizures in patients 1 month of age and older.
Vimpat works differently from most other seizure medications. While many AEDs block the fast inactivation of sodium channels, Vimpat selectively enhances slow inactivation of voltage-gated sodium channels. This unique mechanism helps reduce abnormal electrical activity in the brain without completely shutting down normal nerve signaling.
Vimpat is typically taken twice daily, with doses ranging from 100 mg to 400 mg per day. It's available as tablets, an oral solution, and an IV formulation. It's classified as a Schedule V controlled substance.
For a deeper dive into how this medication works, check out our article on Vimpat's mechanism of action.
There are several reasons you might need to explore alternatives to Vimpat:
The following medications are commonly used for partial-onset seizures and may be considered as alternatives to Vimpat. Each has its own benefits and trade-offs.
Brivaracetam is a newer antiepileptic drug approved for partial-onset seizures in patients 1 month and older. It works by binding to synaptic vesicle protein 2A (SV2A) in the brain — a completely different mechanism from Vimpat.
Key points:
Oxcarbazepine is an established sodium channel blocker used for partial seizures. It's been available for decades, and generic versions are widely accessible.
Key points:
Levetiracetam is one of the most widely prescribed AEDs in the world. It treats both partial-onset and some generalized seizures, and it's available as an affordable generic.
Key points:
Zonisamide is approved as adjunctive therapy for partial seizures in adults. It works through multiple mechanisms, including blocking sodium and calcium channels.
Key points:
If you're considering an alternative to Vimpat, here's how to approach the conversation:
If availability is your main issue, also try finding Vimpat in stock near you before making a switch — the medication may be available at a different pharmacy.
Vimpat is an effective seizure medication, but it's not the only option. If you can't fill your prescription — whether due to supply issues, cost, or side effects — alternatives like Briviact, Trileptal, Keppra, and Zonegran are worth discussing with your neurologist.
Every person with epilepsy is different, and what works for one patient may not work for another. The most important thing is to never change or stop your seizure medication without medical guidance. Work with your doctor to find the safest path forward.
In the meantime, check Medfinder to see if Vimpat is available at a pharmacy near you — you might find it closer than you think.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.